Member Info for Laura2022

Yes patientinvestor

I have posted the Daily Mail article on PYC board

Excuse me

I didn't mention pyc , another poster did

I was correcting your disingenuous and false information, and as for 9mthd funding that is another lie

Anyway

Good luck to VAL and the team in their fight againt this horrible disease

Yes Trevor

Is is incredibly undervalued having just received £380,000 from a placing in June amd already had about £450,000 or more as shareholder funds

And as others have pointed out anyone of our main client could easily just buy PYC

No one is disputing that VAL rightfully stand to gain handsomely from VAL201 ad other pipeline drugs.

PYC and VAL are wotking collaborative ways to end particularly brutal illness like endometriosis for women and prostate cancer for men

Please don't rubbish another share through with incorrect information

I believe Suzy will do well and we need more females as Ceos

Thankyou Freddie

Hope this works Trevor,below was a post from Kidlington and if you click on his username you will find other interesting information

Excellent client summary10 Aug 2023 12:11

PYC have recently had new collabs from Bicycle, who raised appox $240m.

They helped with Cellcentric with CCS1477 ( now inobrodib )and they have just raised approx $20m and had fast track orphan status from FDA.

Numab secured $110m funding in 2021.

You could hope that a fraction of those $ or £ raised ( at least ) could come PYC's way to help with projects either already started or in the future from these companies?

Then there is the 6m from VAL for (201) if that ever gets off the ground that is.

If you look at the Numab pipeline link i posted earlier, you can see that 8 of the 9 projects have partners, including: 3SBio/Sunshine Guojian, Boehringer Ingelheim, Eisai, CStone, Ono, Kaken, and Tillotts.

They have 1 which is fully owned by themselves which is NM32-2668

Its not out of the realms of possibilities that IF PYC are helping Numab on pipeline with a partner, then said partner could also be informed of PYC work?

My buy order was rejected/unfilled

I will try tomorrow

Trevor

It is well worth reading this excellent summary from a contributor called Kidlington

All those touched by cancer are rooting for VAL and PYC to succeed in their own ways and also interrelated with VAL201 for prostate cancer

I believe Suzy will get the deal done

PM

2 very disingenuous points there

As you well know PYC stand to gain up to £6mln from a ßucccessful VAL201 deal and also the cash burn is not high at all, in fact one of the lowest medical company overheads on AIM

POLB article can be a read across to PYC because

1) PYC have many links to ĢSK including CEO and advisors

2) PYC are A.I and machine learning for drug discovery

3) PYC can cut down the time and mistakes in getting drugs lassed by the FDA and its new Project Optimus guidelines which PYC wrote an article about ( see.RNS a few months ago)

Yes Trevor you are right

And also if luck happens £6mln potentially comes to PYC if VAL get their funding for a joint asset on prostate cancer

Pyc helped with data modelling for VAL and in return can get up to £6mln in installments should VAL get the funding (see VAL discussion group)

Also many of PYC clients have raised £20mln to £200mln each to spend on R and D

Good afternoon Trev

Some excellent posts over the last few weeks particularly by Ralph and Kidlington

Anyone one of our clients could easily buy out PYC for multiple ratios of the current value of £1mln

We also have £800,000 cash and just won a "substantial" contract last week

Pyc are one of only a handful of true A.I medical companies listed in the UK,

Huge interest in medical A.i

There have been articles now in about 4 different media outlets

At £1.2mln market value PYC is so undervalued

Cannot buy still

Hopefully one is mine as still not filled and as you say you cannot buy on HL

A.I in medicine is all over the media so worth checking /looking at pyc

Moving up but my order still hasn't been filled ,

Yes citywatcher

I have had a buy order for 350,000 still not filled ,rejected 2 times so I have upped to 3.5p

PYC GSK A.I

This was posted by Kidlington a few days ago

The article can also be viewed here https://jpet.aspetjournals.org/content/early/2023/06/22/jpet.122.001572

On this link you can see where all the other contributors are academically based/work for. Shows that employees/consultants of PYC are in contact scientifically ( at least) with some big companies ( AZ & GSK) on papers.

David Hodson, Hitesh, Leo and Kayode are Uni Manchester.

James Yates is GSK.

Paul Farrington, Anna Staniszewska, Sofia Guzzetti, Michael Davies are all AstraZeneca

: GlaxoSmithKline has begun using AI to make its medical treatments more personalised for individual patients

These recruitment efforts are often the longest part of the drug development process, but GSK said that using AI has allowed it to analyse massive quantities of data, making some parts of the clinical trial procedure up to five times faster.

AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients.

For example, when developing a new drug to treat chronic hepatitis B – a disease which has no cure and kills almost 900,000 people every year – GSK said it took data from an earlier trial and used AI to identify five different patient groups and to predict how they would respond to a new drug. This could increase the chances of success by up to seven times.

In the lab, AI is being used to help GSK's scientists assess hundreds of potential root causes for a disease in the time it previously took to assess just one.

Kim Branson, GSK's head of AI, told The Mail on Sunday: 'AI is game-changing for drug discovery. Our research teams used to look at potential drug targets individually, but they can now investigate hundreds at a time.

'We have already been able to use AI to cut the time it takes to recruit patients for clinical trials, crunch through many times more data than a human being can and categorise patients to predict their response to a potential treatment.'

Daily Mail artiicle ,ad Kidlington pointed out over the weekend, PYC have links to GSK Glaxo and if I recall PYC Ceo used to work there

https://www.thisismoney.co.uk/money/markets/article-12400081/Glaxo-AI-game-changer-medicine.html?ito=amp_twitter_share-top